Advances in Laboratory Methodologies and Biological Matrices for the Study and Management of Rare Ocular Genetic Diseases

Highlights: What are the main findings? The integration of genomic diagnostics with tear-fluid ncRNA profiling has been methodically restructured and quantitatively assessed, illustrating that disease-associated microRNAs and tRNA-derived fragments can be longitudinally quantified in conjunction with genetic diagnoses in inherited ocular disorders. Cross-disease regulatory non-coding RNA networks (angiogenic, hypoxic, inflammatory, fibrotic) originating from age-related macular degeneration, diabetic retinopathy, and proliferative vitreoretinopathy have been distinctly reclassified as mechanistic analogues rather than mere evidence substitutes for inherited retinal diseases, offering a substantiated hypothesis-driven justification for the translational application of tear-omics. What are the implications of the main findings? The integrated genomes and tear-omics approach offers a precision-level monitoring model that can detect molecular decline 4–9 months prior to structural changes observed on OCT, thereby creating a viable surveillance opportunity for IRD intervention and clinical trial stratification. The updated integrative pipeline and newly calibrated quantitative parameters (RNA yield thresholds, ncRNA detection percentages, predictive AUC ranges) transition tear-omics from an exploratory biomarker concept to a viable clinical framework, facilitating reproducible risk assessment and future IRD-specific validation. Rare genetic ocular diseases represent a heterogeneous group of disorders that significantly impair visual function and quality of life. Despite their clinical relevance, many of these conditions remain insufficiently characterized due to complex molecular mechanisms and diagnostic limitations. Recent advances in molecular diagnostics, particularly Next-Generation Sequencing (NGS), have enabled comprehensive and accurate identification of pathogenic variants, offering novel insights into genotype–phenotype correlations and supporting precision medicine approaches. In parallel, the use of alternative biological matrices such as tear fluid has emerged as a promising non-invasive strategy for biomarker discovery and disease monitoring. Tear-based omics, including proteomics and transcriptomics, have identified diagnostic signatures and pathogenic mediators such as non-coding RNAs, microRNAs, and tRNA-derived fragments (tRFs). Among these, tRF-1001 has shown potential both as a biomarker and therapeutic target in ocular neovascular conditions through its modulation of angiogenic pathways. The objective of this review is to show the integration of two rapidly advancing yet frequently isolated fields: next-generation sequencing-based genomics and tear-fluid molecular profiling, positioning them as complementary foundations of precision ophthalmology for rare inherited retinal and optic nerve disorders. Previous reviews have mainly concentrated on either genetic diagnosis or ocular surface biomarkers separately; however, we have introduced a convergent model wherein genomic data furnish diagnostic and prognostic clarity, while tear-omics deliver dynamic, minimally invasive assessments of disease activity, treatment efficacy, and persistent neurovascular stress. By explicitly connecting these two aspects, we have delineated how multi-matrix, multi-omics approaches can expedite early diagnosis, facilitate personalized longitudinal monitoring, and direct focused treatment interventions in rare ocular genetic illnesses.